UKHSA investigation after patient found to have Clade Ib mpox with no links to confirmed cases
An investigation is under way after health chiefs found a new case of mpox in a UK patient. The individual found with the disease has with no known links to other confirmed cases.
The UKHSA also says the person has not travelled to affected countries. Now it is trying to establish where the virus has been contracted.
It said on Monday it has "detected a single confirmed human case of Clade Ib mpox where the case had no reported travel history and no reported link with previously confirmed cases in the UK."
READ MORE: Fruit juice costing 10p could slash cholesterol and blood pressure
READ MORE: Major change announced about missed NHS appointments
It added: "More work is ongoing to determine where the individual, who is resident in the North East of England, may have caught the infection. The individual was diagnosed in March, all contacts have been followed up and no further cases identified.
"The risk to the UK population remains low. Clade Ia and Ib mpox are no longer classified as a high consequence infectious disease (HCID). UKHSA has robust mechanisms in place to investigate suspected cases of mpox of all clade types, irrespective of travel history.
"All previous cases in the UK to date have either travelled to an affected country or have a link to someone that has." The Agency set out signs of mpox to watch for.
It said: "Common symptoms of mpox include a skin rash or pus-filled lesions which can last 2 to 4 weeks. It can also cause fever, headaches, muscle aches, back pain, low energy and swollen lymph nodes." Further information about symptoms is available on the NHS website.
UKHSA Mpox Incident Director Dr Gillian Armstrong said: "The risk to the UK population from mpox remains low. The majority of people who have presented with symptoms report close physical contact, including massages, or sex prior to developing symptoms.
"Regardless of whether you have travelled or not, it is important to remain alert to the risks. Anyone who thinks they may have mpox should contact NHS 111 for advice on what to do.
"While mpox infection is mild for many, it can be severe for some and UKHSA is committed to preventing its spread within the UK."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hornets players invite fans to sign up for special stair climb
Watford players are inviting people to join a special stair climbing event and help make a difference in the community. Vicarage Road Stadium will host the Step Up Challenge on July 5, coinciding with the 77th birthday of the NHS. Defenders James Morris and James Clarridge and midfielders Anna Filbey and Leo Ramirez-Espain are encouraging fans to participate. The event, open to football lovers, fitness aficionados, and families, will see participants walking, running, or climbing through the 20,000-plus seat stadium. The money raised will go towards enhancing the health and wellbeing of thousands of local residents through Watford FC's Community Sports and Education Trust and West Herts Hospitals Charity. The Step Up Challenge will take place on July 5, which coincides with the 77th birthday of the NHS. (Image: Watford FC Trust) Anna, who is ambassador for West Herts Hospitals Charity, said: "We're excited to invite fans to take part in the Step Up Challenge at Vicarage Road. "It's a fantastic way to support our local NHS hospitals and Watford FC's Community Trust, while celebrating 77 years of the NHS's incredible service." The funds generated will aid West Herts Hospitals Charity in its mission to enhance patient care and staff welfare across at Watford General, Hemel Hempstead and St Albans City hospitals. The charity recently funded a new 'Wellbeing Courtyard' at Watford General, providing patients with access to fresh air and a peaceful retreat for NHS staff to recharge. The Step Up Challenge is suitable for all, offering both a full and half route. The event is suitable for all, offering a full and half route. (Image: Watford FC Trust) There is a £15 registration fee for adults (18 years and over) and a £5 fee for young people (6–18 years). To join the challenge at Vicarage Road Stadium on Saturday, July 5, visit the registration link via The event is not only an opportunity for participants to challenge themselves but also a chance to contribute towards a vital cause, supporting healthcare in the local community. Whether you're a fitness enthusiast looking to set a new personal record or someone wanting to enjoy a unique challenge while supporting healthcare, the Step Up Challenge is an initiative that combines fitness, fun, and philanthropy. Join Watford FC players in this one-of-a-kind event and make a difference in the community.
Business Upturn
an hour ago
- Business Upturn
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
MINNEAPOLIS, United States: HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. This press release features multimedia. View the full release here: The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
2 hours ago
- Yahoo
Hospice charity submits plans for care facility
A hospice charity has submitted plans to develop an end-of-life care facility in a coastal town 18 years after fundraising began. Yare Hospice Care launched in 2007, changing its name to East Coast Hospice two years later. In 2023 the charity merged with St Elizabeth Hospice, based in Ipswich. The charity says it wants to build a community hospice with 16 beds on its site at Sidegate Lane in Gorleston near Great Yarmouth. Judi Newman, chief executive of St Elizabeth Hospice, said: "We are delighted to submit this planning application and share our full plans with the wider community." Plans to build a hospice between Lowestoft and Great Yarmouth have stalled for almost two decades as rival charities competed over plans, sites and funding. The community was split over supporting the James Paget University Hospital wanting to build a hospice at the Louise Hamilton Cancer Centre, within its site or the independent East Coast Hospice, which had land and won planning consent for a 10-bed unit. After the NHS withdrew its plans, East Coast Hospice merged with St Elizabeth which immediately conducted a feasibility study which found a hospice was needed to help patients in Great Yarmouth and Waveney. It said the previous plans were not suitable to the needs identified in its report, and it appointed Norwich-based LSI Architects. The proposed unit would feature 16 inpatient beds, an outpatient and community hub for day care and therapies as well as a community café. Roberta Lovick, ambassador for the Louise Hamilton Trust, said: "The strength of our partnership will help us achieve our vision of bringing greater parity to end-of-life care in Great Yarmouth and Waveney. "When my daughter Louise died in 1998, I vowed to dedicate my life to improving end-of-life care in this community and across the country, and this project, alongside St Elizabeth Hospice, is a significant step toward that goal. "This is something we know the community wants and needs. This community hospice building will make a drastic difference to so many people, improving local end-of-life care, giving people more options and support during their precious remaining time with loved ones." Ms Newman added: "We are delighted to submit this planning application and share our full plans with the wider community. "With the invaluable support of Roberta Lovick and the Louise Hamilton Trust, we are in a strong position to develop the community hospice sustainably in a single phase." Ed Garratt, chief executive at Norfolk and Waveney ICB (N&W ICB), said: "This is a hugely welcome development, which aligns with our ambitions to enhance palliative and end-of-life care in our region. "I wholeheartedly support this shared commitment from the voluntary sector, NHS and community in working together to improve services for the local population." Follow Norfolk news on BBC Sounds, Facebook, Instagram and X. New hospice needed in East Anglia, charity says Hospital pulls out of hospice plan
